Kitamura Y, Hayashi K, Sasagawa T, Oguma H, Takasaki K
Department of Surgery, Institute of Gastroenterology, Tokyo Women's Medical University, 8-1, Kawada-cho, Shinjuku, Tokyo, 162-8666 Japan.
Drugs Exp Clin Res. 2003;29(3):125-30.
The prognosis for patients with advanced gastric cancer remains poor. Peritoneal metastasis is the most frequent cause of death in patients with gastric cancer, but the most appropriate treatment for patients with disseminated gastric cancer remains uncertain. S-1 is a newly developed oral fluoropyrimidine derivative with unusually high activity against several tumor types. The aim of this study was to evaluate the feasibility and efficacy of S-1 for the treatment of patients with disseminated gastric cancer. A total of 31 patients with primary or recurrent gastric cancer with peritoneal dissemination were entered into this study. One course of this single-drug therapy consisted of S-1 (80-120 mg) twice daily for 28 days, followed by a 2-week period of no treatment. These treatments were repeated until disease progression or patient refusal. With a median follow-up period in survivors of 293 days, the median survival time was 357 days. Toxicities were mild and no patient withdrew from treatment before disease progression. Grade 3 hematotoxicity was observed in only one patient. S-1 showed promising activity against gastric cancer with peritoneal dissemination and acceptable toxicity. Further evaluation of S-1 treatment is warranted in this disease.
晚期胃癌患者的预后仍然很差。腹膜转移是胃癌患者最常见的死亡原因，但对于播散性胃癌患者最合适的治疗方法仍不确定。S-1是一种新开发的口服氟嘧啶衍生物，对多种肿瘤类型具有异常高的活性。本研究的目的是评估S-1治疗播散性胃癌患者的可行性和疗效。共有31例原发性或复发性胃癌伴腹膜播散的患者进入本研究。这种单药治疗的一个疗程包括S-1（80-120毫克），每日两次，共28天，随后为期2周的无治疗期。这些治疗重复进行，直到疾病进展或患者拒绝。幸存者的中位随访期为293天，中位生存时间为357天。毒性较轻，没有患者在疾病进展前退出治疗。仅1例患者观察到3级血液毒性。S-1对伴腹膜播散的胃癌显示出有前景的活性和可接受的毒性。对这种疾病进行S-1治疗的进一步评估是有必要的。
